Profile data is unavailable for this security.
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
- Revenue in USD (TTM)35.95m
- Net income in USD-104.99m
- Incorporated2015
- Employees104.00
- LocationC4 Therapeutics Inc490 Arsenal Way, Suite 120WATERTOWN 02472United StatesUSA
- Phone+1 (617) 231-0700
- Fax+1 (302) 655-5049
- Websitehttps://c4therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Silence Therapeutics plc | 25.81m | -65.01m | 282.46m | 115.00 | -- | 3.35 | -- | 10.94 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 289.64m | 275.00 | -- | 0.0316 | -- | 1.28 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 293.63m | 124.00 | -- | 1.73 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 298.59m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 299.66m | 110.00 | -- | -- | -- | 7.45 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 300.49m | 71.00 | -- | 2.34 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 308.24m | 28.00 | -- | 1.74 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 308.64m | 4.00 | -- | 1.38 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 309.32m | 104.00 | -- | 1.20 | -- | 8.60 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 312.62m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 317.68m | 148.00 | -- | 2.28 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Neurogene Inc | 0.00 | -85.13m | 321.26m | 107.00 | -- | 1.15 | -- | -- | -4.12 | -4.12 | 0.00 | 17.97 | 0.00 | -- | -- | 0.00 | -37.67 | -27.58 | -40.40 | -29.44 | -- | -- | -- | -28,431.03 | -- | -- | 0.0001 | -- | -- | -- | -106.91 | -- | -1.67 | -- |
| Immuneering Corp | 0.00 | -62.50m | 322.85m | 54.00 | -- | 1.39 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 326.05m | 23.00 | -- | 3.50 | -- | 1,698.17 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to C4 Therapeutics Inc's reporting currency: US Dollar USD
52.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 31 Dec 2025 | 9.44m | 9.74% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 8.97m | 9.26% |
| RA Capital Management LPas of 31 Dec 2025 | 8.00m | 8.26% |
| Lynx1 Capital Management LPas of 31 Dec 2025 | 7.10m | 7.32% |
| Wasatch Advisors LPas of 31 Dec 2025 | 4.34m | 4.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.86m | 3.99% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 3.80m | 3.93% |
| SilverArc Capital Management LLCas of 31 Dec 2025 | 1.99m | 2.06% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.83m | 1.89% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 1.78m | 1.83% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
